ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
60 747,09
-0,08%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) Actualités

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MDGL
DateHeureSourceTitreSymboleSociété
07/05/202422h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202422h34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202422h29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
24/04/202422h00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
23/04/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
16/04/202422h05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
09/04/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
19/03/202404h58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
18/03/202421h04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/03/202412h30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/03/202421h15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
05/03/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202413h01GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202413h00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202412h32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/02/202420h50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
08/02/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of MedicineNASDAQ:MDGLMadrigal Pharmaceuticals Inc
29/01/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Additions to Its Leadership TeamNASDAQ:MDGLMadrigal Pharmaceuticals Inc
26/01/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
04/01/202414h00GlobeNewswire Inc.Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
03/01/202422h30GlobeNewswire Inc.Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
13/12/202322h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
22/11/202323h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
21/11/202314h00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
10/11/202314h00GlobeNewswire Inc.Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver HealthNASDAQ:MDGLMadrigal Pharmaceuticals Inc
10/11/202313h30GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/11/202314h00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
02/11/202321h05GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL

Dernières Valeurs Consultées

GATE
OUSDUSDT
Origin Dollar
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés